Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retroviral targeted delivery

B S Schnierle1, B Groner

  • 1Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany.

Gene Therapy
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib.

MedChemComm·2018
Same author

O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.

Leukemia·2017
Same author

Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.

Clinical and experimental immunology·2013
Same author

c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.

Oncogene·2011
Same author

Direction of the recognition specificity of cytotoxic T cells toward tumor cells by transduced, chimeric T-cell receptor genes.

Methods in molecular medicine·2011
Same author

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.

Vaccine·2009
Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
See all related articles

Researchers are engineering retroviral vectors for gene therapy. They aim to target specific human cells by modifying viral envelope proteins, but challenges remain in achieving precise cell recognition.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Virology

Background:

  • Systemic gene delivery holds promise for advanced gene therapy applications.
  • Retroviral vectors are being explored for systemic gene delivery, necessitating targeted infection capabilities.
  • Current gene therapy vectors often lack specificity, leading to off-target effects.

Purpose of the Study:

  • To review strategies for engineering retroviral vectors with defined target cell specificity.
  • To discuss the modification of murine retroviral envelope proteins for expanded host range and human cell targeting.
  • To analyze the successes and limitations of current approaches to viral target cell recognition manipulation.

Main Methods:

  • Engineering of retroviral envelope proteins to include binding sites for specific cell surface receptors.

Related Experiment Videos

  • Modification of murine retroviruses to alter tropism and infect human cells.
  • Review of published literature on strategies for targeting retroviral vectors.

    • Main Results:

    • Attempts to engineer retroviral envelope proteins have shown promise in expanding host range.
    • Introduction of specific binding sites can direct viral entry to target cells.
    • Significant challenges and pitfalls exist in achieving precise and reliable target cell specificity.

    Conclusions:

    • Engineering retroviral vectors for targeted gene therapy is a complex but crucial area of research.
    • While strategies exist to manipulate viral tropism, overcoming inherent difficulties is essential for clinical success.
    • Further development is needed to ensure the safety and efficacy of engineered retroviral vectors for systemic gene therapy.